Analytical Data
-
基因名
HLA-A*11:01&B2M&KRAS G12A(VVVGAAGVGK) Monomer
- Application
-
别名
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAV53343.1 (G25-T305)&P61769
-
表达区间
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVVGAAGVGK
-
分子量
52-62 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*11:01, B2M, and KRAS G12A monomeric recombinant protein represents a significant area of research in the context of cancer immunotherapy and precision medicine. HLA-A*11:01 is a major histocompatibility complex (MHC) class I molecule crucial for presenting antigens to CD8+ T cells, playing an essential role in anti-tumor immunity. The KRAS G12A mutation is prevalent in various cancers, particularly pancreatic, colorectal, and lung cancers, and it alters the protein's function, leading to unchecked cell proliferation. By investigating the monomeric form of the HLA-A*11:01/B2M/KRAS G12A protein complex, researchers aim to better understand the interactions between the immune system and cancer cells harboring this specific mutation. The recombinant protein allows for detailed structural and functional analyses, potentially paving the way for novel therapeutic strategies that could enhance T cell recognition and response against tumors expressing KRAS mutations. This approach may facilitate the design of peptide-based vaccines or adoptive T cell therapies tailored to target KRAS G12A, thereby providing valuable insights into improving clinical outcomes for patients with KRAS-driven malignancies. Understanding the dynamics of this complex will also contribute to the broader knowledge regarding MHC-restricted antigen processing and presentation, critical for developing effective immunotherapies.
